Neoplasm
Conditions
Brief summary
The primary objective of this study was to assess whether angiotensin blockers (ARBs) and telmisartan in particular, are associated with an increased overall risk of the four most common cancers, namely, lung, colorectal, breast and prostate cancers. A secondary objective was to explore these effects separately for each of the four cancers and in combination with angiotensin-converting-enzyme-inhibitors (ACEIs).
Interventions
Sponsors
Boehringer Ingelheim
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients prescribed an antihypertensive agent between 01-JAN-1995 and 31-DEC-2008 with at least two years of up-to-standard medical history in United Kingdom's General Practice Research Database (GPRD)
Exclusion criteria
* History of cancer at any time prior to cohort entry
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with occurrences of lung, colorectal, breast and prostate cancers related to use of ARBs | 16 years |
| Determination of dose-response in terms of ARB duration of use and cumulative dose and the risk of lung, colorectal, breast and prostate cancers combined | 16 years |
| Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of ARBs, relative to beta-blockers and diuretics | 16 years |
| Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of telmisartan, relative to beta-blockers and diuretics | 16 years |
| Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of telmisartan relative to other ARBs | 16 years |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients with occurrences of colorectal cancer related to use of ARBs with ACEI | 16 years |
| Number of patients with occurrences of breast cancer related to use of ARBs with ACEI | 16 years |
| Number of patients with occurrences of prostate cancer related to use of ARBs with ACEI | 16 years |
| Number of patients with occurrences of lung cancer related to use of ARBs alone | 16 years |
| Ratio of occurrence of colorectal cancer related to use of telmisartan relative to other ARBs | 16 years |
| Ratio of occurrence of breast cancer related to use of telmisartan relative to other ARBs | 16 years |
| Ratio of occurrence of prostate cancer related to use of telmisartan relative to other ARBs | 16 years |
| Ratio of occurrence of lung cancer related to use of telmisartan relative to other ARBs | 16 years |
| Number of patients with occurrences of colorectal cancer related to use of ARBs alone | 16 years |
| Number of patients with occurrences of breast cancer related to use of ARBs alone | 16 years |
| Number of patients with occurrences of prostate cancer related to use of ARBs alone | 16 years |
| Number of patients with occurrences of lung cancer related to use of ARBs with ACEI | 16 years |
Outcome results
None listed